# ALA-105

Source: https://onco.cc/drugs/ala-105/  
OnCo record `ala-105` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ALA-105 is an experimental CAR-iNKT cell therapy with IL-12 armouring from Arovella Therapeutics, at a stage the company does not state for gastric cancer, gastro-oesophageal junction cancer and pancreatic cancer.

## Summary

ALA-105 (CLDN18.2-iNKT) is a CAR-iNKT cell therapy with IL-12 armouring from Arovella Therapeutics, with Sparx Group as partner. iNKT cells carrying a CAR built from Sparx's anti-CLDN18.2 antibody SPX-101, armoured with membrane-tethered IL-12 (IL-12-TM) to improve persistence in solid tumours. The company does not state its stage; it is aimed at gastric cancer, gastro-oesophageal junction cancer and pancreatic cancer. No clinical trial naming it is registered on ClinicalTrials.gov. No registry trial found (ClinicalTrials.gov query for ALA-105 returned none); the company page gives no stage, so 'preclinical' is inferred from the absence of any trial. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Last checked: 2026-11-03
- Also known as: CLDN18.2-iNKT
- Tags: pipeline
- Code: ALA-105
- Modality: CAR-iNKT cell therapy with IL-12 armouring
- Mechanism: iNKT cells carrying a CAR built from Sparx's anti-CLDN18.2 antibody SPX-101, armoured with membrane-tethered IL-12 (IL-12-TM) to improve persistence in solid tumours.

## Sources

- Arovella Therapeutics: arovella.com: https://www.arovella.com/ala-105-cldn182-inkt
- Arovella Therapeutics: arovella.com: https://www.arovella.com/ala-105-cldn182-inkt

## Connected records

- targets: [Claudin 18.2](https://onco.cc/targets/cldn18-2/)
- companies: [Arovella Therapeutics](https://onco.cc/companies/arovella-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/ala-105.json